After more than two decades as a Big Pharma cancer leader, Nicholas Botwood is swinging into the biotech world as the new ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Despite securing a much-needed $5 million lifeline from an equity offering this week, HCW Biologics is continuing to warn ...

BioMarin has followed through on its shift to external innovation, inking a deal to buy Inozyme for $270 million to add a phase 3 enzyme replacement therapy to its pipeline.

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of ...

WASHINGTON, D.C.—FDA Commissioner Martin Makary, M.D., offered more details into the agency’s recently announced plans to ...